Background: Competing hypotheses have been formulated about a possible association between selective serotonin reuptake inhibitors (SSRIs) and ischemic stroke. However, the relationship between antidepressant drug use and ischemic stroke is still unclear. Aim of the study was to assess the association between use of diff erent types of antidepressants and the risk of ischemic stroke in elderly outpatients. Methods: A population-based, nested, case-control study was conducted in persons 65 years and older in the Integrated Primary Care Information (IPCI) database (1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005). Cases were all patients with a validated fi rst ischemic stroke. Controls were matched on year of birth, sex and index date. Exposure to antidepressants was divided in current, past and non-use and further categorized by type (SSRI, tricyclic [TCA], other antidepressants), dose and duration. Conditional logistic regression was used to compare the risk of ischemic stroke between users of antidepressants and non-users. Results: Overall, 996 incident ischemic strokes were identifi ed. Current use of SSRIs was associated with a signifi cantly increased risk as compared to non-use (OR: 1.55; 95 CI: 1.07-2.25) in elderly, particularly when used longer than 4 months. No associations were observed for current use of TCAs and other AD. Conclusion: Compared to non use, only SSRI use appears to be associated with an increased risk of ischemic stroke in elderly patients, particularly as short term eff ect.
BACKGROUND
Antidepressant drugs (ADs) are widely used in elderly people for indications such as depressive symptoms, anxiety disorders and neuropathic pain [1] [2] .
Th e selective serotonin reuptake inhibitors (SSRIs) are considered the fi rstchoice for the elderly with depressive symptoms, as these drugs are supposed to have similar effi cacy to other antidepressants but better tolerability [3] . Recently, the eff ects of SSRIs on cerebral circulation have garnered attention after preliminary reports suggested an association between SSRI exposure and risk of abnormal bleeding, including hemorrhagic stroke [4] [5] [6] . SSRIs decrease the intracellular contents of serotonin in platelets by blocking serotonin transporter 5-HTT, thus inhibiting platelet function. Th is anti-platelet eff ect of SSRIs may ultimately increase the risk of hemorrhage, such as intracranial bleeding [7] . Th e same mechanism might theoretically protect against arterial thrombotic events, including ischemic stroke [7] . Previous investigations documented a signifi cant reduction in the risk of myocardial infarction associated with SSRI use [8] [9] . On the other hand, SSRIs may cause vasoconstriction in cerebral arteries as a result of serotoninergic activation which may lead to ischemic stroke [10] [11] . To date the net eff ect of SSRIs on the risk of ischemic and hemorrhagic stroke remains unclear.
Several studies explored the association between hemorrhagic stroke and SSRI and other antidepressant drug use but failed to show any signifi cant associations [12] [13] [14] . Little is known about the risk of ischemic stroke in elderly persons using antidepressants, although approximately 80 of total strokes are ischemic ones in these patients [15] .An Italian study did not fi nd an increased risk of cerebrovascular adverse eff ects in elderly patients who were treated with antidepressants, but did not diff erentiate between ischemic and hemorrhagic stroke [16] . Two studies did demonstrate an increased risk of ischemic stroke for SSRIs but did not consider the elderly specifi cally [17] or were limited to hospitalized stroke only and not considering other antidepressants and indication of use [18] . Altogether, the epidemiologic evidence about antidepressant use and risk of ischemic stroke is inconclusive.
Th us, the aim of this study was to assess the association between the use of various antidepressant drug types and the risk of a fi rst-ever ischemic stroke in community-dwelling elderly persons.
METHODS

Setting
We employed a population-based, nested, case-control study. Data for this study were retrieved from the Integrated Primary Care Information (IPCI) database. Th e IPCI database is a longitudinal general practice research database set up in 1992 and containing data from electronic medical records from a group of 150 Dutch general practitioners' (GPs) practices. In the Netherlands, all persons have their own GP who serves as the gatekeeper to medical care and fi les all relevant medical details on their patients from primary care visits, hospital admissions and visits to outpatient clinics. A detailed description of the database has been previously reported [19]. Briefl y, IPCI contains the medical records of approximately 800,000 patients with an age and gender distribution representative of the Netherlands. Th e electronic records contain coded and anonymous data on patient demographics, reasons for visits, signs, symptoms and medical diagnoses (using the International Classifi cation for Primary Care [20] ) from GPs and specialists, hospitalizations, as well as drug prescriptions. Drug prescriptions include product name, anatomical therapeutic chemical (ATC) classifi cation, dispensed quantity, dosage regimen and coded indication. To maximize completeness of the data, GPs participating in the IPCI project are not allowed to maintain a system of paperbased records, aside from the electronic medical records. Th e system complies with European Union guidelines on the use of medical data for medical research and has been proven valid for pharmaco-epidemiological research [21] . Th e Scientifi c and Ethical Advisory Board of the IPCI project approved the study.
Study population
Th e study started on January 1, 1996, and ended on December 31, 2005. Th e source population comprised all individuals 65 years and older with at least 1 year of data registered in the database. All individuals were followed from the study entry date until one of the following events, whichever came fi rst: transient ischemic attack (TIA), stroke, death, moving out of the practice area, or end of the study period. Patients who had a recorded diagnosis of TIA or stroke in the medical history prior to the study entry were excluded. Patients with a diagnosis of cerebral tumor, either before or during the study period, were also excluded.
Case Identifi cation and Ascertainment
Cases were all patients with a fi rst-ever ischemic stroke that occurred during the study period. Th e case identifi cation and ascertainment included two phases. First, we applied a broad search on patient clinical diary and summaries of specialist letters, using coded diagnoses and key words for free text. Second, the electronic medical records of all potential cases of cerebrovascular accidents were manually reviewed by two medically trained researchers (G.T. and E.F.S), who were blinded to the exposure. Patients were classifi ed as having a TIA, a hemorrhagic stroke, an undefi ned stroke, or an ischemic stroke. Ischemic stroke was considered if the diagnosis was confi rmed by a CT-scan or explicitly mentioned by a consulting specialist or listed among discharge diagnoses. Th e date of initial symptoms (e.g. dizziness, unexplained falling, and headache) was considered as the index date. Only if a stroke was preceded by a TIA occurring less than one month before, TIA was taken as the index date. Otherwise, a TIA was not considered in order to avoid case misclassifi cation. TIA, however, was used as a censoring point to avoid protopathic bias since some patients with TIA may receive treatment with antidepressants subsequently [22] . In case of disagreement between the two assessors in classifying the cases and identifying the index date, a consensus was found via discussion. For each case, all persons in follow-up at the time of the index date and of the same age and sex as the case served as a control in the statistical analyses.
Exposure defi nition
Information on antidepressant drug use was obtained from the prescription fi les. We created antidepressant exposure categories based on drug type, and recency, dose and duration of use. Th e legend duration was calculated as the total number of units per prescription divided by the prescribed daily number of these units. Antidepressant drugs were grouped according to the mechanism of action into: 1) Selective serotonin reuptake inhibitors (SSRIs): paroxetine, fl uoxetine, citalopram, fl uvoxamine and sertraline; 2) Tricyclic antidepressants (TCAs): clomipramine, amitriptyline, dothiepin, imipramine, trimipramine, lofepramine, maprotiline, doxepin, nortriptyline, desipramine, bupropion, moclobemide, opipramol, dosulepin and reboxetine; 3) Other antidepressants: venlafaxine, mirtazapine, mianserine, nefazodone and trazodone. A combination category was considered for concomitant use of more antidepressants belonging to diff erent classes. We performed a secondary analysis in which we grouped antidepressant drugs based on the affi nity to the serotonin transporter [14]: 1) high affi nity (paroxetine, fl uoxetine, sertraline, and clomipramine); 2) intermediate affi nity (citalopram, fl uvoxamine, amitriptyline, dothiepin, imipramine, and venlafaxine); 3) low affi nity (trimipramine, lofepramine, maprotiline, doxepin, nortriptyline, desipramine, bupropion, moclobemide, opipramol, dosulepin, reboxetine, mirtazapine, mianserine, nefazodone and trazodone). Exposure to diff erent types of antidepressants was further divided into current, past and never use. Drug use was defi ned as current if the prescription length covered the index date or ended less than 30 days (carry-over eff ect) prior. Past use meant that the last prescription ended more than 30 days prior to the index date. Patients were defi ned as non users if antidepressant prescriptions were never recorded prior to the index date. To be able to study the dose-eff ect, we expressed daily dosing regimens as the prescribed number of defi ned daily dosages (DDD), as defi ned by the World Health Organization (see website: http://www.whocc.no/atcddd/indexdatabase/). Duration of antidepressant use was calculated as the cumulative number of prescription days during the follow-up period. Th e duration was divided into short term use if ≤180 days and long term use if >180 days, as the median duration of any antidepressant use was 180 days.
Covariates
As potential confounders, we considered age, sex, and calendar time (matching factors), smoking cigarettes, presence of cardiovascular disease (heart failure, hypertension, angina, history of myocardial infarction, peripheral arterial disease, atrial fi brillation, phlebitis/thrombophlebitis), neuropsychiatric diseases (Parkinson's disease, dementia, and migraine), chronic obstructive pulmonary disease (COPD), diabetes mellitus, lipid metabolism disorders, coagulation/platelet abnormalities, malignant tumors, pneumonia (within 3 months prior to the index date). We also considered chronic use of diuretics, digoxin, ACE-inhibitors, angiotensin receptor blockers, calcium-channel blockers, beta-blockers, lipid-lowering drugs, vasodilators and concomitant use (within 3 months prior to index date) of low dose aspirin, anticoagulants, antibiotics, systemic corticosteroids, NSAIDs, benzodiazepines, antipsychotic drugs, and opioids. Depression itself may be a risk factor for stroke and therefore confounding by indication cannot be easily ruled out [23] . To address this issue, two medically trained researchers (G.T. and E.F.S.) manually assessed the indication of use of antidepressant drugs from the free text of the medical records. Reasons for use were classifi ed as depression, anxiety, headache, neuropathic pain, and other/unspecifi ed disorders. Th is approach was taken for all exposed cases and for a randomly selected sample of the exposed controls (N=425).
Data Analysis
Relative risks of ischemic stroke plus 95 confi dence intervals [CIs] were estimated by calculating odds ratios by using conditional logistic regression analysis. We performed adjustment for all covariates that were associated with ischemic stroke at the univariate analyses. In these analyses current and past use of diff erent types of antidepressants (SSRI, TCA and other antidepressants) were compared to non-use. To compare directly the risk for ischemic stroke among diff erent antidepressant types, we performed an additional analysis with current use of TCA as comparator. A secondary analysis was carried out considering as exposure categories antidepressants with high, intermediate and low affi nity to the serotonin transporter. A linear trend across strata of increasing affi nity to the serotonin transporter was tested by including affi nity as an ordinal variable in the logistic regression model. A sensitivity analysis was conducted in which we removed the carry over eff ect of 30 days. Among current users of antidepressants, we further calculated odds ratios for the risk of ischemic stroke with individual medications, daily dosage (≤ 0.5 and > 0.5 DDD), and cumulative duration of use (≤ 180 days and >180 days). Stratifi ed analyses were conducted to study age and history of ischemic vascular disease as eff ect modifi ers. To evaluate the presence of confounding by indication we also performed an analysis according to the type of antidepressant and the indication of use.
Antidepressant drugs may be prescribed to treat symptoms of cerebral ischemic disorders occurring shortly before stroke, thus some cases of ischemic stroke could be mistakenly attributed to antidepressant exposure (i.e. protopathic bias). To further assess the possible eff ect of protopathic bias on the association between antidepressants and ischemic stroke, we performed sensitivity analyses in which all patients, who started antidepressant treatment within 30, 60 and 90 days before the index date, were excluded. All analyses were conducted in SPSS/PC, version 13 (SPSS Inc, Chicago, Ill). Th e level of signifi cance for all statistical tests was 2-sided P < 0.05.
RESULTS
Th e source population for this study comprised 70,392 individuals of 65 years and older. Of them, 1,176 (1.7) were excluded because of cerebral tumors (n= 138) or history of cerebrovascular event (n=1,038) prior to the study entry. Th e fi nal study population comprised 69,216 elderly persons (43 males, average age: 72.7±7.6 years). Within this population, 1,354 (2.0) persons experienced a fi rst-ever stroke (ischemic, hemorrhagic and undefi ned subtypes) during the study period, of which 996 (74) were classifi ed as incident ischemic stroke. Per case there were on average 493 age and sex matched controls available as a comparator. Demographic and clinical characteristics of cases and controls are reported in Table 1 . Co-morbidities like hypertension, coronary heart diseases, atrial fi brillation, coagulation abnormalities, diabetes mellitus, COPD, and dementia, and concomitant use of corticosteroids, anticoagulants and opioids were associated with ischemic stroke. Among cases, 151 (15.2) received at least one antidepressant drug at any time Table 3) . Th e indication of use was validated and assessed in all the cases (N=152) and in a sample of controls (N=425), who were currently or formerly exposed to an antidepressant drug. Among the 52 cases, 36 (69) were currently treated with antidepressants because of depressive symptoms, and two thirds of these subjects received SSRIs ( * Analysis was adjusted for hypertension, angina, history of myocardial infarction, atrial fi brillation, heart failure, coagulation/platelet abnormalities, COPD, diabetes mellitus, dementia, concomitant use of anticoagulants, systemic corticosteroids and opioids. Legend: 1. Paroxetine, fl uoxetine, sertraline, clomipramine; 2. Citalopram, fl uvoxamine, amitriptyline, dothiepin, imipramine, venlafaxine; 3. Trimipramine, lofepramine, maprotiline, doxepin, nortriptyline, desipramine, bupropion, moclobemide, opipramol, dosulepin and reboxetine, mirtazapine, mianserine, nefazodone and trazodone.
the eff ect of the association between antidepressant and ischemic stroke (data not shown). To test for protopathic bias, we excluded patients who received the fi rst prescription of antidepressant within 30, 60 and 90 days prior to the index date. Compared to non-use, the risk in current users was only somewhat diluted (from 1.55 to 1.42 for SSRI; from 1.18 to 1.01 for TCA; from 1.01 to 1.07 for other antidepressants). Although our analysis was underpowered to assess the risk of each individual drug, sertraline (4 exposed cases, OR: 2.03; 95 CI: 0.76-5.44) and paroxetine (18 exposed cases, OR: 1.59; 95 CI: 1.00-2.55) were associate with the greatest risks of ischemic stroke.
DISCUSSION
To our knowledge, this is the fi rst observational study that explored specifi cally the association between antidepressant drug use and the risk of ischemic stroke in a cohort of elderly patients. Th e results show that in comparison to non use, current use of SSRIs confers a signifi cantly increased risk of ischemic stroke (adj. OR: 1.55; 95 CI: 1.07-2.25), especially during the fi rst 6 months of treatment. [18] . In this study the analytic strategy could have resulted in a misclassifi cation of the index date and, as a result, a misclassifi cation of the exposure. We did found an association between past use of both SSRIs and TCAs and the risk of ischemic stroke. Th is fi nding could point at a potential eff ect of confounding by indication on our results. Depression itself is a known risk factor of cerebrovascular disorders in young patients [23] [24] , while the role of depression as predictor of stroke in elderly patients remains very controversial [24] . To deal with confounding by indication, Chen et al recently conducted a nested casecontrol study among patients with depression in a large population-based, U.S. medical claims database [17] . In line with our study, the risk of ischemic stroke for current users of SSRIs was signifi cantly higher as compared to non-use (adj. OR: 1.55; 95 CI: 1.00-2.39), while the increase in the risk in current users of TCAs (OR: 1.59; 95CI: 0.89-2.83) or other antidepressants (OR: 1.33; 95CI: 0.81-2.17) was not statistically signifi cant. Also, in our study, when we selected exclusively depressed elderly (depression as the indication for treatment), only SSRI use was associated with an increased risk of stroke. TCA or other antidepressants show no association whatsoever. Th is fi nding argues against the infl uence of confounding by indication. Possible mechanisms supporting a potential causal association between exposure to SSRIs and ischemic stroke have been previously hypothesized. Serotoninergic activation secondary to SSRI use can induce a vasoconstrictive eff ect that is mediated by the 5-hydroxytryptamine-2 (5HT-2) receptor on smooth muscle cells [25] [26] . A recent review about the cerebrovascular eff ects of SSRIs pointed out that use of these medications may increase the risk of ischemic stroke by triggering thromboembolism through its vasoconstrictive eff ect in patients with large cerebral arteries atherosclerosis [7] . A signifi cant linear trend between the risk of ischemic stroke and the affi nity to the serotonin transporter was evident in our study. Also, paroxetine and sertraline, antidepressants showing the highest affi nity to the serotonin transporter [27], seemed to confer a greater risk of ischemic stroke. Th ese fi ndings support the hypothesis that a serotoninergic activation may play a role in the association between ischemic stroke and SSRI use. Th e eff ect of SSRIs was predominantly observed within the fi rst six months of therapy, which could point at an immediate eff ect of SSRIs and depletion of susceptibles during continued use.
Strength and limitations
Th e strength of this study is the availability of information on many confounders and details on antidepressant use. Moreover, we were able to review the medical records of all potential cases to identify the real incident, fi rst-ever ischemic strokes. However, several limitations warrant caution. As in any observational study, selection bias, information bias and residual confounding should be considered as alternative explanations for the study fi nding. Selection bias was minimal as all data were obtained from prospectively collected medical records that are maintained for patient care purposes. To minimize the potential eff ect of information bias by misclassifi cation of the outcome a two-step case validation was undertaken and, for the same purpose, TIA itself was not considered as a study endpoint, due to high probability of misclassifi cation for this event. However, if a stroke was preceded by a TIA occurring less than one month before, the case was retained and the onset of TIA was taken as the index date.
To exclude all patients with history of cerebrovascular events at the study entry, we required at least one year of data registered in the database as inclusion criteria. Nevertheless, we could have missed information on prior cerebrovascular events without sequelae occurring long time before the study entry. Misclassifi cation of exposure cannot be excluded since we used outpatient prescription data and had no information about whether the drug prescriptions were actually fi lled and taken. Non-adherence to antidepressant medication may be a relevant issue particularly in older patients, although a U.K. study reported that the level of adherence did not diff er across various antidepressant types in community dwelling elderly [28] . Not fi lling of prescriptions or non-adherence most likely results in non-diff erential misclassifi cation of the exposure, in which case our study underestimates the actual risk. Moreover, we may have missed specialist prescriptions of antidepressants. Many risk factors for ischemic stroke were considered in our study. Despite this, residual confounding due to unmeasured confounders or severity of (underlying) disease cannot be excluded. It is however unlikely that highly prevalent and strong risk factors were missed in our study. Finally, since the study considered only community dwelling elderly, the fi ndings may not be generalized to elderly inpatients or those living in nursing homes. Likewise, exclusion of patients with prior TIA or stroke prevents the generalizability of the results to elderly patients with a prior history of cerebrovascular events.
In summary, our study shows that among elderly people living in the community current use of SSRI may increase the risk of ischemic stroke, especially within the fi rst 6 months of treatment. Further studies employing larger samples are needed to confi rm these results and to conclusively establish the eff ect of the affi nity to the serotonin transporter. Meanwhile, it seems advisable that SSRI treatment is carefully tailored and that a close monitoring is established in the fi rst few weeks of treatment.
